CD274 and breast cancer: Recently, studies suggested that it represents a mediator of the stage progression in BC [28], with BC patients expressing high PD-L1 levels showing a poor prognosis and relapse-free survival [29], and with an unfavorable prognosis in immune checkpoint-treated naive ccRCCs [30].